Schering GMP Work Plan Is One-Third Complete; Toughest Battles Lie Ahead
This article was originally published in The Tan Sheet
Executive Summary
The remaining two-thirds of Schering-Plough's GMP work plan contain the most challenging requirements under the company's 2002 manufacturing consent decree, CEO Fred Hassan told analysts Nov. 18
You may also be interested in...
Schering: Competitor Switch Of Rx Antihistamine, Nasal Steroid Anticipated
Schering-Plough expects the over-the-counter switch or generic availability of a competing Rx antihistamine or nasal steroid to impact its 2004 fiscal year earnings
Schering Continues To Feel Symptoms From Claritin Switch With Net Loss
Sales of Schering-Plough's OTC Claritin (loratadine) allergy drug rebounded from a poor second quarter but the impact of the switch from Rx status continued to drag down the firm's overall earnings
Schering Cost Cuts Run Deep: Consumer Health Unit In Danger Of Divestiture?
Schering-Plough will retain its Consumer Health Care business in the near-term but may choose to sell the unit as it undertakes a broad restructuring plan that includes an unprecedented dividend slash to cut costs